Predictors of diastolic dysfunction in rheumatoid arthritis

Rajalingham Sakthiswary, MD, MRCP, Srijit Das, MBBS, MS.

ABSTRACT

The main objective was to determine the predictors of diastolic dysfunction in rheumatoid arthritis (RA). Articles pertaining to diastolic dysfunction in RA were retrieved from Scopus, EBSCO, PubMed, Web of Science, and Cochrane Library databases. Keywords such as: diastolic, cardiac, left ventricular function, heart failure, rheumatoid arthritis, and cardiac failure were used. Studies, which examined factors, or predictors of diastolic dysfunction in RA, and those with echocardiographic evaluation of diastolic dysfunction, were included. A total of 8 studies met the eligibility criteria. Most studies (6 out of 7 studies) demonstrated a significant inverse relationship between the E (early)/A (late) ratio and disease duration. The pooled analysis using the random effects model revealed a significant but weak inverse relationship between the ratio of the E to A ventricular filling velocities (E/A) ratio and the disease duration (p<0.05, r=-0.385). There was a significant relationship between E/A ratio and disease duration in RA.

From the Department of Medicine (Sakthiswary), and the Department of Anatomy (Das), The National University of Malaysia, Cheras, Kuala Lumpur, Malaysia.

Address correspondence and reprint request to: Dr. Srijit Das, Department of Anatomy, 18th Floor, Pre-Clinical Block, The National University of Malaysia, Jalan Yaacob Latif, Bandar Tun Razak 56000, Cheras, Kuala Lumpur, Malaysia. Fax: +6 (03) 91458607. E-mail: drsrijit@gmail.com

Disclosure. Authors have no conflict of interests, and the work was not supported or funded by any drug company. This systematic review was supported by the “Dana Lonjakan Penerbitan” research grant of The National University of Malaysia, Cheras, Kuala Lumpur, Malaysia.

Saudi Med J 2015; Vol. 36 (5): 525-529 doi: 10.15537/smj.2015.5.10751
**Search strategy and study selection.** We retrieved all published studies on diastolic dysfunction in RA from Scopus, EBSCO, PubMed, Web of Science, and the Cochrane Library databases. Keywords such as: diastolic, cardiac, left ventricular function, heart failure, rheumatoid arthritis, and cardiac failure were used. The study was conducted between April and June 2014 at Medical Center, The National University of Malaysia, Cheras, Kuala Lumpur, Malaysia. We also scrutinised the bibliographies of all published articles to avoid missing any potentially relevant study. The abstracts of published studies were independently reviewed and assessed by both authors. Only those articles deemed appropriate and considered eligible by both authors, were included in this systematic review. Figure 1 summarizes the algorithm used for the selection of the studies. We used a stringent set of study criteria to ensure a high level of homogeneity across the selected studies. The inclusion criteria included: 1) Studies that examined factors or predictors of diastolic dysfunction in RA, 2) Studies with echocardiographic evaluation of diastolic dysfunction. We excluded studies written in other languages apart from English, articles such as: case reports, letters to the editor, supplements, and review articles. Studies with juvenile onset RA were also excluded.

**Outcome measures.** Numerous echocardiographic parameters were used in the studies namely E/A ratio (the ratio of the early (E) to late (A) ventricular filling velocities), left ventricular (LV) mass, left atrial volume index, LV end diastolic diameter, isovolumetric relaxation time (IVRT), early and late diastolic flow velocity. To date, there is a lack of a comprehensive consensus regarding diagnostic echocardiographic criteria for diastolic dysfunction. However, echocardiographic evaluation of diastolic function traditionally involves the measurements of transmural flow parameters, including the E and A diastolic filling velocities, the E/A ratio, and the E deceleration time (DT) from an apical 4 chamber. The most common index of diastolic function used in these series of studies was E/A ratio. Hence, we focused on factors associated with this parameter. The following data were extracted from the selected studies: year of publication, study design, sample size, echocardiographic parameters: (E/A ratio, LV mass, early diastolic flow velocity, late diastolic flow velocity, IVRT), and associated clinical parameters (disease activity, disease duration, age, and so forth). The quantitative differences in the aforementioned parameter between the RA patients, and the controls were recorded. The data were pooled using a random effects model for a more conservative estimate of the correlation between the E/A ratio and clinical parameters. The advantage of this model is that it allows for heterogeneity across the studies. The results of the correlation analysis were expressed as a correlation coefficient (r) and p-value. Comprehensive Meta-analysis software version 2.0 (Biostat, Englewood, NJ, USA) was used to generate the Forest plot for the pooled data.

**Study types and characteristics.** A total of 8 studies met the eligibility criteria for this systematic review. Table 1 summarizes the selected studies. These studies were published between years 1999 and 2013. Half of the selected studies were conducted in Europe. Interestingly, all were case-control, cross-sectional, and observational studies. The controls were homogenous across the studies. Healthy subjects with unknown medical illness served as controls in all the studies. The sample sizes in this series of studies ranged from 65 to 1692 subjects. In most of the studies, the ‘cases’ were defined as patients with RA without any evidence of cardiovascular disease.

**Disease duration.** Seven out of 8 of the studies with a total of 2243 subjects investigated the correlation between diastolic dysfunction and the disease (RA) duration. Most of the studies (6 out of 7 studies) demonstrated a significant inverse relationship between the E/A ratio and the disease duration. The only exception was a study by Montecucco et al, which...
## Table 1 - Summary of the selected studies on diastolic dysfunction in rheumatoid arthritis.

| Reference            | Country  | Study population                                            | Outcome measures                          | Findings                                                                                                                                 |
|----------------------|----------|-------------------------------------------------------------|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Montecucco et al 1999 | Italy    | 54 RA patients without obvious CVD                         | LV mass                                   | No significant difference between the patients and controls                                                                          |
|                      |          | 54 age- and gender-matched normal subjects                  | E/A ratio                                 | RA patients had significantly lower values than control subjects (1.1±0.34 versus 1.32±0.45; p=0.003). Correlated with patient age but was independent of disease duration, LV mass and blood pressure |
| Rexhepaj et al 2006   | Germany  | 81 patients with RA without clinically evident CVD         | E                                         | RA versus controls                                                                                                                     |
|                      |          | 40 healthy subjects                                        | E/A ratio                                 | 0.68±0.19 m/s versus 0.84±0.14 m/s, p<0.001                                                                                             |
|                      |          |                                                             | A                                         | 0.73±0.15 m/s versus 0.66±0.13 cm/s, p=0.01                                                                                             |
|                      |          |                                                             | E/A ratio                                 | 0.79±0.3 versus 1.32±0.37, p<0.001                                                                                                      |
|                      |          |                                                             | E/A ratio and duration of RA              | There was a weak correlation (r=-0.22, p=0.001)                                                                                       |
| Arslan et al 2006     | Turkey   | 52 patients with active RA                                 | A                                         | Higher in patients with RA than that in the control group (p<0.001)                                                                 |
|                      |          | 47 healthy controls                                        | E/A ratio                                 | Lower in patients with RA than that in the control group (p<0.001)                                                                 |
|                      |          |                                                             | E/A ratio                                 | The following correlated significantly with disease duration:                                                                            |
|                      |          |                                                             |                                           | r=-0.43, p=0.001                                                                                                                      |
|                      |          |                                                             |                                           | r=0.40, p=0.004                                                                                                                       |
| Canturk et al 2006    | Turkey   | 34 patients with RA without evidence of CVD                | E, A and the E/A ratio                    | RA versus controls                                                                                                                     |
|                      |          | 34 healthy controls                                        | E/PV (propagation velocity) ratio of the RA patients | No statistically significant difference                                                                                               |
|                      |          |                                                             | E/PV ratio of the patients who have disease more than 10 years significantly higher than the patients who have the disease for 5-9 years (p<0.01) and 0-4 years (p<0.01) |
| Di Franco et al 2000  | Italy    | 32 patients with RA without evidence of CVD                | E/A ratio                                 | RA versus controls                                                                                                                     |
|                      |          | 33 healthy controls                                        |                                           | 1.16±0.31 versus 1.37±0.32; p=0.02                                                                                                      |
|                      |          |                                                             |                                           | Correlated with disease duration (r=-0.40, p=0.01)                                                                                      |
|                      |          |                                                             |                                           | There was no statistically significant correlation between all echocardiographic parameters and disease activity, presence of rheumatoid factor, number of joints involved, or Ritchie index |
| Udayakumar et al 2007 | India    | 45 patients with RA without evidence of CVD                | E/A ratio                                 | RA versus controls                                                                                                                     |
|                      |          | 45 healthy controls                                        |                                           | 0.98±0.22 versus 1.09±0.11; p=0.004                                                                                                      |
|                      |          |                                                             |                                           | 75.7±8.12 ms versus 70.4±2.94 ms; p=0.001                                                                                              |
|                      |          |                                                             |                                           | 76.9±11.61 cm/s versus 70.11±5.32 cm/s; p=0.001                                                                                         |
|                      |          |                                                             |                                           | Correlation with disease duration                                                                                                     |
|                      |          |                                                             |                                           | r=0.56, p=0.001                                                                                                                       |
|                      |          |                                                             |                                           | r=0.66, p=0.01                                                                                                                       |
|                      |          |                                                             |                                           | r=0.61, p=0.001                                                                                                                       |
|                      |          |                                                             |                                           | no statistically significant differences in gender, presence of extra articular manifestations, and cumulative prednisone doses were found |
| Liang et al 2010      | USA      | 244 subjects with RA with 1448 non-RA subjects             | LV mass                                   | RA versus controls                                                                                                                     |
|                      |          |                                                             | E/A ratio                                 | 83.1±15.6 versus 88.3±20.4; p=0.001                                                                                                      |
|                      |          |                                                             |                                           | 1.76±0.59 versus 1.09±0.37, p<0.001                                                                                                     |
|                      |          |                                                             |                                           | Correlated with                                                                                                                        |
|                      |          |                                                             |                                           | A) Disease duration (OR: 3.2, 95% CI: 1.8-5.4)                                                                                          |
|                      |          |                                                             |                                           | B) Interleukin 6 levels (OR: 1.2, 95% CI: 1.02-1.4)                                                                                      |
|                      |          |                                                             |                                           | (After adjustment for cardiovascular risk factors)                                                                                      |
| Tomas et al 2013      | Slovakia | 60 patients with RA                                         | E/A ratio                                 | RA versus controls                                                                                                                     |
|                      |          | 30 healthy controls                                        |                                           | 1.11±0.05 versus 1.32±0.07; p<0.05                                                                                                     |
|                      |          |                                                             |                                           | There were no correlations of NT-proBNP and TNF-alpha.                                                                                 |

RA - rheumatoid arthritis, CVD - cardiovascular disease, E - early ventricular filling velocity, A - late ventricular filling velocity, NT-proBNP - N-terminal-proBrain natriuretic peptide, OR - odds ratio, CI - confidence interval, LV - left ventricular, IVRT - isovolumetric relaxation time, TNF - tumor necrosis factor
found no association between these 2 variables. We performed a pooled analysis using the data from 4 studies\textsuperscript{12,14,17,19} in order to determine the relationship between the E/A ratio and disease duration. Three of the studies\textsuperscript{13,15,16} were not included in the analysis as the values of the correlation coefficient (r) were not available. Our pooled analysis revealed a significant but weak inverse relationship between E/A ratio and disease duration ($p<0.05$, $r=-0.385$). Figure 2 illustrates the Forest plot on the correlation between E/A ratio and disease duration.

**Cytokines interleukin 6 and tumor necrosis factor-α (TNF-α).** Liang et al\textsuperscript{15} found that interleukin (IL) 6 levels were independently associated with diastolic dysfunction even after adjustment for cardiovascular risk factors (odds ratio [OR]: 1.2, 95% confidence interval [CI]: 1.02-1.4). Tomas et al\textsuperscript{18} reported that TNF-α levels had a significant inverse relationship with E/A ratio. Unfortunately, our literature search failed to identify other studies examining the association between cytokines and diastolic dysfunction.

**Demographic and clinical characteristics.** Few of the selected studies investigated the association between diastolic dysfunction and the following demographic, and clinical characteristics namely age, disease activity, seropositivity, number of joints involved, Ritchie index, extra articular manifestations, and cumulative prednisolone doses.\textsuperscript{14,16,19} Apart from a single study\textsuperscript{16} showing a correlation between age and E/A ratio, none of the remaining studies observed any other risk factors for diastolic dysfunction in RA. The findings of the present systematic review depict a significant inverse relationship between E/A ratio; an echocardiographic parameter of diastolic function, and duration of RA. Although the strength of the relationship was weak ($r=-0.385$), there was convincing evidence to support disease duration as a clinical predictor of diastolic dysfunction in RA. Although only 4 studies were included in the statistical analysis, it is noteworthy to mention that the remaining 2 out of 3 studies\textsuperscript{13,15} demonstrated a trend towards deterioration of diastolic function with disease duration. Liang et al\textsuperscript{15} reported that the above association remained significant even after adjustment for traditional cardiovascular risk factors such as diabetes mellitus, smoking, and hypertension. The exact mechanism to explain this link still remains ill defined. However, researchers hypothesized that in RA there could be an ongoing subclinical myocardial inflammatory process, which leads to impairment of myocardial function.\textsuperscript{12,15}

In RA, cytokines like IL6, IL1, IL17, IL23, and TNF-α are produced in abundance.\textsuperscript{11} Dinh et al\textsuperscript{20} reported that increased plasma levels of IL6 and TNF-α were associated with left ventricular diastolic dysfunction. It is tempting to speculate that a pro-inflammatory pathway may be one of the key orchestrators of diastolic dysfunction in RA. Keeping these findings in view, Liang et al\textsuperscript{15} and Tomas et al\textsuperscript{18} demonstrated a significant relationship between E/A ratio and IL6 and TNF-α levels. There is growing evidence suggesting that cytokines directly mediate hypertrophic remodeling and myocardial fibrosis through regulation of collagen synthesis and matrix metalloproteinase activity of the cardiac fibroblasts.\textsuperscript{21} Unfortunately, much of this evidence was derived from animal studies.\textsuperscript{22,23} Owing to the paucity of studies investigating the linking nexus between cytokines and diastolic dysfunction in RA, no firm conclusions could be made in this regard.

Montecucco et al\textsuperscript{16} reported that E/A ratio in RA correlated to the age of the patients. These findings were similar to many other population-based studies,\textsuperscript{24,25} which had proven the age-related deterioration in parameters of diastolic function. Most studies included in this review did not analyze the relationship between age and E/A ratio, probably due to the well-established influence of age on diastolic function, which requires no further verification. However, the inversion of the E/A ratio was observed at a younger age in the RA patients compared with the control, which lend credence to the notion of earlier deterioration of diastolic function in RA.\textsuperscript{16}
There are a few limitations to this systematic review. Several factors may confound the reported findings in the selected studies. Observer bias should be considered as most studies did not specify if the echocardiography was blinded or not. The E/A ratio was by far the most frequently used echocardiographic parameter to assess diastolic function in the studies. Hence, we used this variable in our pooled analysis. In clinical practice, assessment of diastolic function is based on a combination of parameters such as IVRT, propagation velocity and intraventricular dispersion of E wave velocity. This limits the generalizability of our findings.

In conclusion, our systematic review indicates that there is concrete evidence supporting a significant relationship between E/A ratio and disease duration in RA. There are no robust data to suggest the role of other clinical or biochemical factors as predictors of diastolic dysfunction in RA.

References

1. Widdifield J, Paterson JM, Bernatsky S, Tu K, Tomlinson G, Kuriya B, et al. The epidemiology of rheumatoid arthritis in Ontario, Canada. *Arthritis Rheumatol* 2014; 66: 786-793.

2. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously--predictive markers, socioeconomic status and comorbidity. *J Rheumatol* 1986; 13: 841-845.

3. Listing J, Kekow J, Manger B, Burmester GR, Parthoch D, Zink A, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF inhibitors and rituximab. *Ann Rheum Dis* 2015; 74: 415-421.

4. Nicola PJ, Crowson CS, Maradit-Kremers H, Ballman KV, Roger VL, Jacobsen SJ, et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. *Arthritis Rheum* 2006; 54: 60-67.

5. Segers VF, De Keulenaer GW. Pathophysiology of diastolic dysfunction in chronic heart failure. *Future Cardiol* 2013; 9: 711-720.

6. Maniu CV, Redfield MM. Diastolic dysfunction: insights into pathophysiology and pharmacotherapy. *Expert Opin Pharmacother* 2001; 2: 997-1008.

7. Davis JM 3rd, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, et al. A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. *Arthritis Rheum* 2011; 63: 1497-1506.

8. Aslam F, Bandeli SJ, Khan NA, Alam M. Diastolic dysfunction in rheumatoid arthritis: a meta-analysis and systematic review. *Arthritis Care Res (Hoboken)* 2013; 65: 534-543.

9. Mottram PM, Marwick TH. Assessment of diastolic function: what the general cardiologist needs to know. *Heart* 2005; 91: 681-695.

10. Dereimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7: 177-188.

11. Wonggratanacheewin S. Significant role of cytokines and signaling pathway in rheumatoid arthritis, nasal polyposis and human airway smooth muscle cells. *Asian Pac J Allergy Immunol* 2013; 31: 1-2.

12. Arslan S, Bozkurt E, Sari RA, Erol MK. Diastolic function abnormalities in active rheumatoid arthritis evaluation by conventional Doppler and tissue Doppler: relation with duration of disease. *Clin Rheumatol* 2006; 25: 294-299.

13. Canturk F, Yazici M, Alayli G, Menekse EB, Demircan S, Ibrahimli F, et al. Combined use of propagation velocity and intraventricular dispersion of E wave velocity for the evaluation of diastolic functions in patients with rheumatoid arthritis. *Int J Cardiovasc Imaging* 2006; 22: 369-376.

14. Di Franco M, Paradiso M, Mammarella A, Paoletti V, Labbadia G, Coppotelli L, et al. Diastolic function abnormalities in rheumatoid arthritis. Evaluation by echo Doppler transmitral flow and pulmonary venous flow: relation with duration of disease. *Ann Rheum Dis* 2000; 59: 227-229.

15. Liang KP, Myasocedova E, Crowson CS, Davis JM, Roger VL, Karon BL, et al. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. *Ann Rheum Dis* 2010; 69: 1665-1670.

16. Montecucco C, Gobbi G, Perlini S, Rossi S, Grandi AM, Caporali R, et al. Impaired diastolic function in active rheumatoid arthritis. Relationship with disease duration. *Clin Exp Rheumatol* 1999; 17: 407-412.

17. Rexhepaj N, Bajraktari G, Berisha I, Beqiri A, Shatri F, Hima F, et al. Left and right ventricular diastolic functions in patients with rheumatoid arthritis without clinically evident cardiovascular disease. *Int J Clin Pract* 2006; 60: 683-688.

18. Tomas L, Lazurova I, Oetterova M, Kundova L, Petrasova D, Studencan M. Left ventricular morphology and function in patients with rheumatoid arthritis. *Wien Klin Wochenscr* 2013; 125: 233-238.

19. Udayakumar N, Venkatesan S, Rajendiran C. Diastolic function abnormalities in rheumatoid arthritis: relation with duration of disease. *Singapore Med J* 2007; 48: 537-542.

20. Dinh W, Futh R, Nickl W, Krahn T, Ellinghaus P, Scheffold T, et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. *Cardiovasc Diabetol* 2009; 8: 58.

21. Murray DR, Freeman GL. Proinflammatory cytokines: predictors of a failing heart? *Circulation* 2003; 107: 1460-1462.

22. Ohki S, Oshima K, Tsutsumi H, Koike N, Matsumoto K, Takeyoshi I. The suppression of proinflammatory cytokines improves heart function from non-heart-beating donors following transplantation in a canine model. *Int Heart J* 2009; 50: 235-245.

23. Xing SS, Bi XP, Tan HW, Zhang Y, Xing QC, Zhang W. Overexpression of interleukin-18 aggravates cardiac fibrosis and diastolic dysfunction in fructose-fed rats. *Mol Med* 2010; 16: 465-470.

24. Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Bonnema D, Zile MR. Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. *Am J Physiol Heart Circ Physiol* 2010; 298: H614-H622.

25. Carvalho JC, Parand P, Do HD, Brochu MC, Bonenfant F, Lepage S. Effect of age and sex on echocardiographic left ventricular diastolic function parameters in patients with preserved ejection fraction and normal valvular function. *Cardiol J* 2013; 20: 513-518.